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Abstract
 
Chemokines have been hypothesized to contribute to the selectivity of lymphocyte trafficking
not only as chemoattractants, but also by triggering integrin-dependent sticking (arrest) of cir-
culating lymphocytes at venular sites of extravasation. We show that T cells roll on most Peyer’s
patch high endothelial venules (PP-HEVs), but preferentially arrest in segments displaying high
levels of luminal secondary lymphoid tissue chemokine (SLC) (6Ckine, Exodus-2, thymus-
derived chemotactic agent 4 [TCA-4]). This arrest is selectively inhibited by functional deletion
(desensitization) of CC chemokine receptor 7 (CCR7), the receptor for SLC and for macrophage
inflammatory protein (MIP)-3
 
b 
 
(EBV-induced molecule 1 ligand chemokine [ELC]), and does
not occur in mutant DDD/1 mice that are deficient in these CCR7 ligands. In contrast, pertussis
toxin–sensitive B cell sticking does not require SLC or MIP-3
 
b
 
 signaling, and occurs efficiently
in SLC
 
low/
 
2
 
 HEV segments in wild-type mice, and in the SLC-negative HEVs of DDD/1
mice. Remarkably, sites of T and B cell firm adhesion are segregated in PPs, with HEVs sup-
porting B cell accumulation concentrated in or near follicles, the target domain of most B cells
entering PPs, whereas T cells preferentially accumulate in interfollicular HEVs. Our findings
reveal a fundamental difference in signaling requirements for PP-HEV recognition by T and B
cells, and describe an unexpected level of specialization of HEVs that may allow differential, seg-
mental control of lymphocyte subset recruitment into functionally distinct lymphoid microen-
vironments in vivo.
Key words: receptors, lymphocyte homing • receptors, chemokine • cell adhesion • 
endothelium, vascular • lymphoid tissue
 
Introduction
 
Recirculating naive lymphocytes are recruited from the
blood stream into the secondary lymphoid tissues of Peyer’s
patches (PPs)
 
1
 
 and LNs via selective interactions with high
endothelial venules (HEVs). Lymphocyte recognition of HEVs
involves a multistep adhesion cascade in which primary
adhesive interactions (rolling) are followed by firm arrest
(sticking) in response to pertussis toxin (PTX)-sensitive rapid
signaling events (1–3; for a review, see reference 4). Although
the functional contribution of endothelial and lymphocytic
adhesion molecules has been characterized (1–5), the iden-
tity and physiological roles of the signaling receptor(s) and
their ligand(s) involved in lymphocyte–HEV recognition
have not been defined.
Recent evidence has highlighted the potential role in
lymphocyte migration and homing of a relatively new class
of soluble leukocyte chemoattractants called chemokines,
which signal through PTX-sensitive G
 
a
 
i
 
-linked serpentine
receptors (6, 7). PPs and peripheral LNs (PLNs) express
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Abbreviations used in this paper:
 
 CCR, CC chemokine receptor; CM-
FDA, carboxymethylfluorescein diacetate; cRPMI, RPMI 1640 supple-
mented with 10% bovine calf serum and 10 mM Hepes; CXCR, CXC
chemokine receptor; DNP, dinitrophenol; HEV, high endothelial
venule; LM, labeling medium; LNC, LN lymphocyte; MAdCAM, mu-
cosal addressin cell adhesion molecule; MIP, macrophage inflammatory
protein; MLN, mesenteric LN; PLN, peripheral LN; PP, Peyer’s patch;
PTX, pertussis toxin; SDF, stromal cell–derived factor; SLC, secondary
lymphoid tissue chemokine. 
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message RNA for at least three chemokines, including sec-
ondary lymphoid tissue chemokine (SLC) and macrophage
inflammatory protein (MIP)-3
 
b
 
, which act through a com-
mon CC chemokine receptor, CCR7; and stromal cell–
derived factor (SDF)-1
 
a
 
, which signals through CXC che-
mokine receptor (CXCR)4; each of which attracts the
majority of lymphocytes (8–11), including the naive cells
that characteristically home to secondary lymphoid organs
(12). We and others have hypothesized that CCR7 on
lymphocytes may be critical for lymphocyte–HEV interac-
tions because CCR7 ligands are most abundant in second-
ary lymphoid tissues and, in particular, because SLC message
is expressed by endothelial cells of HEVs (10). Furthermore,
recent in vitro studies have demonstrated rapid adhesion and
transendothelial chemotaxis of B and T cells in response to
CCR7 ligands in assays that model in vivo shear and adhe-
sive environments of secondary lymphoid tissues (8, 10, 14,
15). To explore the involvement of CCR7 and its ligands
in physiological lymphocyte interactions with PP-HEVs,
we selectively attenuated CCR7 function in lymphocytes
by ligand desensitization, observed their interactions in situ
using intravital microscopy, and compared their behavior
with that of normal lymphocytes interacting with SLC-
deficient HEVs in DDD/1 mice. In addition, we assessed
the in situ display of CCR7 ligand SLC by PP-HEVs using
confocal microscopy, compared SLC localization with sites
of lymphocyte accumulation, and investigated the differen-
tial accumulation of T and B cells in PP-HEVs.
Our results demonstrate that SLC is displayed by a subset
of HEVs that support T cell arrest, and that absence of SLC
presentation by HEVs or functional inhibition of the SLC/
MIP-3
 
b
 
 receptor CCR7 abrogates the firm arrest of T but
not B cells in PP-HEVs. Together, these data suggest a
critical role for CCR7 in T cell–HEV recognition, and re-
veal a fundamental difference in the signaling requirements
for T and B cell recruitment to PP-HEVs. Furthermore, our
studies demonstrate an unexpected segregation of HEV sites
of T and B cell accumulation within PPs, correlating with
differential chemokine display in well-defined microenvi-
ronmental domains. These results suggest a novel mecha-
nism for the microenvironmental targeting of lymphocyte
subsets, at the level of HEV recognition and recruitment
from the blood.
 
Materials and Methods
 
Reagents.
 
CellTracker™ Green, 5-chloromethylfluorescein
diacetate (CMFDA; Molecular Probes, Inc.) was prepared as a
0.5 mg/ml stock solution in DMSO, stored at 
 
2
 
30
 
8
 
C, and used
within 1 wk. Tetramethylrhodamine-5-(and-6)-isothiocyanate
(5[6]-TRITC; Molecular Probes, Inc.) was prepared as a 2 mM
solution in DMSO, diluted to a stock 1:10 with saline, sterile fil-
tered, and stored in single aliquots at 
 
2
 
30
 
8
 
C. Alexa™ 488 and
Alexa™ 546 protein labeling kits were used as directed by the
manufacturer (Molecular Probes, Inc.). Chemokines mouse SLC
(Exodus-2/thymus-derived chemotactic agent 4 [TCA-4]/6Ckine;
a gift of DNAX Research Institute), human MIP-3
 
b
 
 (ELC), and
human SDF-1
 
a
 
 (PeproTech) were prepared as 0.5 mg/ml stock
solutions in saline and used immediately, or stored as aliquots at
 
2
 
80
 
8
 
C. Labeling medium (LM) was 50% RPMI 1640 and 50%
Ca/Mg-free HBSS (BioWhittaker), supplemented with 1.5% bo-
vine calf serum and 10 mM Hepes (cRPMI) (Sigma Chemical Co.)
and was made fresh daily.
 
mAbs.
 
mAbs Mel-14 (rat IgG2a, anti–mouse L-selectin [16]),
MECA 79 (rat IgM, anti–peripheral node addressin [PNAd]),
MECA 367 and MECA 89 (rat IgM, anti–mucosal addressin cell
adhesion molecule [MAdCAM]-1 [17]), 9B5 (rat IgM, anti–human
CD44), and 4B1E7C10 (hamster IgG, anti–mouse SLC [18]) were
generated in our laboratories. Hybridoma cells for these mAbs as
well as mAbs UC8-1B9 (hamster IgG, anti-dinitrophenol [DNP];
American Type Culture Collection), Tib 213 (rat IgG2b, anti–
mouse CD11a; American Type Culture Collection [19]), and PS/2
(rat IgG2b, anti–mouse CD49d; American Type Culture Collec-
tion) were purified from culture supernatant. mAbs were stored
at 
 
2
 
80
 
8
 
C in endotoxin-free saline at 1 mg/ml. For in situ staining
studies, 12–75 
 
m
 
g of antibody was injected via left carotid arterial
cannulation. FITC-, Alexa™ 488–, and Alexa™ 546–conjugated
mAbs to DNP, human CD44, mouse L-selectin, mouse CD11a,
mouse CD49d, mouse SLC, and mouse MAdCAM-1 were made
in our laboratories. FITC-conjugated mAbs to murine CD3 and
B220 were from PharMingen.
 
Lymphocyte Isolation and Treatment.
 
LN cells (LNCs) were freshly
isolated from PLNs (axillary, brachial, cervical, and subiliac) and
mesenteric LNs (MLNs). Splenocytes were freshly isolated from
disaggregated spleens, and cleared of red blood cells using a
Whole Blood Erythrocyte Lysing kit (R&D Systems). Cells were
incubated for 1 h at 37
 
8
 
C in cRPMI, then washed and resus-
pended to 1.5 
 
3
 
 10
 
7 
 
cells/ml in warm LM. Representative sam-
ples were stained with FITC-conjugated mAbs to T and B cell
markers (CD3 and B220, respectively) and determined by flow
cytometry to be 
 
z
 
95% lymphocytes. For isolation of T and B cell
populations, negative selection columns were used as directed by
the manufacturer (R&D Systems, and Cedarlane). Purity as de-
termined by CD3 or B220 staining was on average 
 
.
 
96% for T
cells, and 
 
.
 
90% for B cells. For fluorescent labeling, 2 ml LNCs
was incubated with 4 
 
m
 
M CMFDA or 0.8 
 
m
 
M TRITC in LM
for 10 min at 37
 
8
 
C. Lymphocytes were centrifuged through 2 ml
of warm bovine calf serum, and supernatant was discarded. The
pellet was resuspended to 1.5 
 
3
 
 10
 
7
 
 cells/ml in warm LM. Ali-
quots of LNCs were treated with chemokine or saline for 45 min,
washed again through serum, resuspended at 1 
 
3
 
 10
 
8
 
 cells/ml in
warm saline, and used immediately.
 
Animals.
 
We used adult BALB/c and DDD/1 (23) mice
(bred in the animal facility of Palo Alto Veterans Medical Center)
of both sexes (10–14 wk, 18–25 g body wt) as recipients for in
vivo experiments, and young BALB/c mice (6–10 wk, 12–20 g
body wt) as lymphocyte donors. All experimental procedures
comply with National Institutes of Health guidelines for the care
and use of laboratory animals, and were approved by the Standing
Committees on Animals of Stanford Medical School and The
Palo Alto Veterans Medical Center. Animals were under com-
plete surgical anesthesia throughout all experimental procedures.
 
PP Preparation and Intravital Microscopy.
 
Mice were anesthe-
tized by intraperitoneal injection (10 ml/kg) of physiologic saline
containing xylazine (1 mg/ml) and ketamine (5 mg/ml). A loop
of small intestine displaying at least one PP was prepared for in-
travital microscopy as described previously (1, 2) with modifica-
tions. In brief, a polyethylene catheter was inserted in the left ca-
rotid artery and was used for injection of cell suspensions and
mAbs. A midline incision was made to expose the peritoneal cav-
ity, and a jejunal or duodenal loop was exposed and arranged 
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within a rubber O-ring upon a small raised platform attached to a
stage, and kept moist with warm saline. After the PP to be exam-
ined was positioned, a glass coverslip was applied to enclose the
preparation for microscopic viewing. The stage was then placed
on a Nikon intravital microscope equipped with a silicon-intensi-
fied target camera (Cohu, Inc.). The PP was visualized by epiflu-
orescence from a mercury lamp source. Video images were re-
corded using a time-base generator (For-A) and a VHS VCR
(JVC). Venular segments to be video-recorded were located by
the characteristic autofluorescence of stromal elements in PP pri-
mary follicles, and identified by characteristic physical structure.
 
Analysis of In Situ Lymphocyte Behavior in PP-HEVs.
 
Boluses
(100–200 
 
m
 
l) of fluorescently labeled LNCs or splenocytes (10
 
8
 
cells/ml) were retrogradely injected via the carotid artery catheter
over 30 s. Lymphocyte behavior in PLNs was recorded through
16
 
3
 
 Neofluor (Nikon) or 20
 
3
 
 water immersion objective (Ach-
roplan; Carl Zeiss, Inc.). Cell behavior in individual vessel seg-
ments was determined by playback of videotapes. For each ex-
periment, cells of one color were selected as the experimental
population, and these cells were resuspended after fluorescent la-
beling to 1.5 
 
3
 
 10
 
7
 
/ml, aliquoted into two tubes, and incubated
with chemokine (desensitized test cells) or control medium (mock-
treated control cells) for 45 min at 37
 
8
 
C, then washed by centrif-
ugation through a serum cushion. Cells of the other color, used
as an internal standard population, were similarly washed after la-
beling, then mixed at 
 
z
 
1:1 ratio with the experimental test or
control cells at a final concentration of 10
 
8
 
 cells/ml in warm sa-
line. (Aliquots of injected mixtures were saved for FACS
 
®
 
 analy-
ses to determine the precise ratio of experimental to standard cells
injected.) Cells were then immediately injected via carotid artery
cannula into mice prepared for intravital microscopy. Areas
within the selected PPs were surveyed in the initial 2 min for
HEVs supporting lymphocyte interactions, and then observed for
an additional 10 min. Microscope filter sets were alternated every
30 s to allow observations of differently labeled (experimental
versus internal standard) cells, thus allowing comparison of be-
havior of identically labeled test (chemokine-treated) cells versus
mock-treated (control) cells, in littermate animals, with the be-
havior of the same internal standard cell population.
The total number of cells entering HEVs in the blood per
minute was defined as the total cell flux. Cells were considered
noninteracting when they moved at the velocity of RBCs, ap-
pearing as streaks on videotape images. These were easily distin-
guished from rolling cells, whose velocity is typically 10-fold
lower: these rolling cells appear as circles on each video frame, and
were characterized by velocities in our experiments 
 
,
 
300 
 
m
 
m/s
(generally 20–150 
 
m
 
m/s, similar to previous reports [2, 3, 43]).
Cells were considered interacting whether they rolled, arrested,
or both. The rolling fraction is the percentage of cells that inter-
act with a given venule in the total number of cells that enter that
venule during the same period. Velocities of 
 
.
 
15 consecutive
rolling lymphocytes were calculated as described (1). Sticking/arrest
or firm adherence was defined as interacting cells that become
immobile for 
 
.
 
3 s (1). Total flux and rolling fraction data were
collected during a period 4–8 min after injection, and represent at
least 10 consecutive cells in at least 10 HEVs per preparation. Ac-
cumulated cells (i.e., cells that did not move during a 30-s obser-
vation) in the same HEV were enumerated at the 8-min time point.
The values of total flux, rolling fraction, or accumulated cell
numbers for the experimental population were normalized to
those of the coinjected internal standard cells assessed within the
HEV and time period, thus controlling for natural variability in
hemodynamics and vascular characteristics. The resulting ratio
provides an index of the behavior of the chemokine-treated test
cells (e.g., the total flux of test cells divided by the flux of internal
standard cells), and this index is then expressed as a percentage of
that of the index of control (mock-treated) experimental cell
flux/internal standard cell flux determined in parallel littermate
animals. The control experiments using the mock-treated cells were
performed immediately before and after those using chemokine
treatments. The use of internal standard populations, and the
analysis of data and results of in vivo homing data in this manner
have been discussed in more detail elsewhere (12).
 
Statistical Methods.
 
Data in graphs are shown as means 
 
6
 
 SD,
unless otherwise indicated. For statistical comparison of two sam-
ples, a two-tailed Student’s 
 
t
 
 test was used when applicable. Dif-
ferences were considered statistically significant when
 
 P 
 
, 
 
0.05.
 
Results
 
Chemokine-desensitized Lymphocyte Interactions in PP-HEVs.
 
Lymphocytes exposed to high concentrations of a chemo-
kine become refractory to subsequent stimulation with the
same chemokine, or other agonists that signal through the
same receptor(s). This selective unresponsiveness is thought
to be mediated by the well-described phenomenon of
ligand-induced homologous receptor desensitization (20, 21).
We have previously shown that SLC and MIP-3
 
b
 
 can de-
sensitize mouse LNCs, as well as human PBLs, and that
these chemokines signal via the same chemokine receptor,
CCR7 (22). Here we asked whether desensitization of lym-
phocytes with SLC, which is expressed by HEVs and can
trigger rapid integrin-mediated adhesion in vitro, could in-
hibit in situ signals that trigger integrin-mediated firm ad-
hesion of rolling lymphocytes. We observed the behavior of
chemokine-treated or control lymphocytes within PP-HEVs,
while recording video images for later analysis. Unfraction-
ated, monocyte-depleted LNCs derived from PLNs and
MLNs were fluorescently labeled, then pretreated with
chemokine or control media before use. Cells were washed
through a warm serum gradient and immediately injected
into a mouse prepared for intravital microscopy.
Desensitization with CCR7 ligand SLC, but not with
the CXCR4 ligand SDF-1
 
a
 
, substantially inhibits accumu-
lation of intravenously injected LNCs in PP-HEVs in vivo
(Fig. 1). Total flux and rolling fraction of SLC-treated lym-
phocytes through HEV were, if anything, slightly increased
over control. Rolling velocity (Fig. 1 legend) and surface lev-
els of adhesion receptors L-selectin, LFA-1, and 
 
a
 
4
 
b
 
7 on
desensitized lymphocytes (data not shown) remained un-
changed from mock-treated control. Chemokine desensiti-
zation dramatically reduced the conversion of rolling to
sticking behavior and firm arrest, an effect that is similar to
PTX treatment and consistent with inhibition of the spe-
cific G
 
a
 
i
 
 protein–linked signaling event required for inte-
grin-mediated activated rapid adhesion.
 
Distinct Requirements for Activation-dependent Arrest of T
versus B Lymphocytes.
 
The incomplete inhibition of LNC
accumulation by SLC desensitization led us to ask if there
was a subset of lymphocytes that could adhere indepen-
dently of CCR7 signaling. We found that SLC or MIP-3
 
b 
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pretreatments dramatically attenuated T cell accumulation,
acting, as above, at the level of triggered firm arrest (Fig.
2 A). Total flux, rolling fraction (Fig. 2 A), and rolling veloc-
ity (see Fig. 2 legend) for treated T cells were indistinguish-
able from control. Although these results do not formally
exclude an effect of SLC or MIP-3
 
b
 
 pretreatment on sig-
naling through other adhesion-triggering receptors, they are
consistent with a requirement for CCR7-dependent T cell
recognition of HEVs. In contrast, preincubation with CCR7
ligands had no effect on B cell behaviors in PP-HEVs (in-
cluding accumulation, Fig. 2 b), even though this treat-
ment effectively inhibited the robust chemotactic response
of B cells to homologously signaling agonists in vitro (Fig. 3).
Importantly, B cell accumulation was inhibited by PTX
treatment, confirming the involvement of a G
 
a
 
i
 
 heterotrimeric
G protein–mediated signaling event (data not shown).
Together, these results suggest that B cell firm arrest in
HEVs is triggered by a chemokine (or other chemoattractant)
receptor independent of or in addition to CCR7.
To evaluate further the apparent difference in T versus B
cell requirement for CCR7 signaling, we took advantage
Figure 1. Desensitization of LNCs with SLC inhibits arrest in PP-HEVs.
Unfractionated LNCs (70–85% CD31 by FACS®) of young mice were
washed and incubated in cRPMI for 1 h in tissue culture flasks. LNCs were
fluorescently labeled, incubated with chemokine (SLC and SDF-1a) or
control medium for 45 min at 378C, washed through a warm serum gra-
dient to remove residual chemokine, and resuspended together with in-
ternal standard cells (labeled in a different color) immediately before in-
jection via carotid artery cannulation into mice prepared for intravital
microscopy. Areas within the visualized PPs were surveyed in the initial 2
min for HEVs supporting lymphocyte interactions, and then observed for
a further 10 min. Total flux and rolling data (for test and for internal stan-
dard cells) were collected during a 2-min period 6–8 min after injection,
and represent at least 10 consecutive cells of each type in at least 10 HEVs
per preparation. Accumulated cells in these same HEVs were enumerated
at the 8-min time point. Lymphocyte total flux, rolling fraction, or accu-
mulation was variable in different vessels and PPs, reflecting the natural
variability in hemodynamic parameters and vascular characteristics. There-
fore, values determined for experimental cells (chemokine-desensitized or
mock-treated cells of one color) were normalized by dividing by values
obtained for coinjected internal standard population (labeled in a separate
color) determined in the same recipient vessels. The ratio of chemokine-
treated cell to internal standard cell values (e.g., rolling fractions), determined
in one set of recipients, was then divided by the ratio of mock-treated
control cell to internal standard cell values determined in littermate recip-
ients, and multiplied by 100. Thus, the data presented represent the total
flux, rolling fraction, or accumulation of chemokine-treated cells ex-
pressed as a percentage of those of mock-treated control cells labeled
identically and analyzed in parallel. Therefore, 100% in the graph repre-
sents the behavior of the mock-treated control cells: for these cells, the
total flux of cells entering HEVs in the blood per minute ranged from 16
to 60, mean 36 6 14 SD in a representative experiment; the rolling frac-
tion ranged from 27 to 100%, mean 69 6 20% SD; and the number of
cells accumulated in HEV segments ranged from 0 to 60 or more by 10
min. These values illustrate the natural variability associated with different
vascular segments and observation periods that necessitated the use of in-
ternal standard cells for these studies. Rolling velocity ranged from 25 to
170 mm/s, mean 81 6 46 SD. Mean results of five experimental animals
for each treatment (6 SD) are shown in the graph. Inhibition of accumu-
lation by SLC treatment is significant compared with SDF-1a or control
treatment by Student’s t test (P , 0.01).
Figure 2. Effect of chemokine desensitization on T and B cell interac-
tions with PP-HEVs. (A) T cell or (B) B cell subpopulations of LNCs
were enriched by negative selection (see Materials and Methods), labeled,
and incubated with 1 mM of indicated chemokine or control medium as
in Fig. 1, then injected (mixed 1:1 with internal standard cells), and their
behaviors were observed within PP-HEVs. Data collection was as in the
legend to Fig. 1 except for B cells (which accumulated faster than T cells;
data not shown), for which total flux and rolling fraction were analyzed
during a 2-min time period 4–6 min after injection. Data are percentages
of mock-treated control, and represent mean results of two to four exper-
imental animals for each combination of subset and treatment (6 SD).
Control T cell total flux in vessels examined ranged from 14 to 60 cells/
min, mean 48 6 24 SD, and rolling fraction from z35 to 93%. Control B
cell total flux ranged from 8 to 74 cells/min, mean 32 6 18 SD, and roll-
ing fraction from 25 to 84%, mean 54 6 23%. Rolling velocity of T cells
(range 23–197 mm/s, mean 94 6 33 SD, comparable to previous reports
[references 2, 41]) was not effected by SLC desensitization (range 24–160
mm/s, mean 99 6 44 SD). B cell rolling velocities were similar (range
27–120 mm/s, mean 55 6 25 SD). Inhibition of T cell accumulation by
SLC or MIP-3b desensitization is significant compared with control or
SDF-1a desensitization by Student’s t test (P , 0.01). 
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of the DDD/1 mouse strain. DDD/1 mice have greatly re-
duced numbers of T cells in LNs and PPs, but have almost
normal B cell numbers. Short-term homing assays suggest
abnormalities in T cell migration into lymphoid tissues, al-
though adhesive interactions between lymphocytes and HEVs
in Stamper-Woodruff frozen section assays were normal
(23, 24). The mice have a genetic defect in one of two
SLC genes (the one expressed in lymph nodes; see Note
added in proof). Lymphoid tissues of DDD/1 mice lack
mRNA for SLC, and MIP-3
 
b
 
 transcription is severely
reduced as well (24). We reasoned that the defect in T cell
lymphocyte homing in DDD/1 mice could be due either to
a deficiency in T cell interactions with HEVs in situ, or else
to an absence of directed migration of HEV-bound cells
into LNs as had been speculated previously (23, 24). To
distinguish between these possibilities, we compared the in
situ behavior of enriched wild-type T and B lymphocyte
populations interacting with PP-HEVs of DDD/1 mice
with their interactions in normal mice. While B cell interac-
tions were similar in recipients of the two genotypes, there
was a striking lack of T cell arrest in DDD/1 PPs (Fig. 4).
The T cell rolling flux in DDD/1 mice was significantly
higher than in normal mice within 6 min, presumably due
to the inability of naive T cells to localize in mutant orga-
nized lymphoid tissues. Thus, lymphocyte behavior in
DDD/1 PP-HEVs is equivalent to that of specific SLC-
and MIP-3
 
b–desensitized T and B cells in normal mice
(Fig. 2).
Our data suggest that CCR7 but not CXCR4 is criti-
cally involved in the triggering of T cell rapid adhesion in
PP-HEVs. In contrast, triggered adhesion and firm arrest of
B cells involve distinct mechanisms independent of (or in ad-
dition to) SLC, MIP-3b, and SDF-1a, and their receptors.
Microenvironmental Control of Lymphocyte Recruitment. We
wished to address further the role of SLC, speculating that
for SLC to trigger adhesion of blood-borne lymphocytes, it
must be presented on the lumen of HEVs. We intravenously
injected fluorescently labeled anti–mouse SLC mAbs, anti–
MAdCAM-1 mAbs, or control mAbs into normal BALB/c
mice for intravital staining of vessel endothelium (Fig. 5).
Anti-SLC reacted with most MAdCAM-11 HEVs in PPs, but
reactivity was variable in different regions. The most in-
tensely staining segments were predominately located within
interfollicular areas, whereas MAdCAM-11 HEVs lacking
detectable SLC were most common in or adjacent to folli-
cles. Presentation of SLC by segments of venular trees
draining individual follicles was also variable, particularly in
Figure 3. Homologous but not heterologous desensitization by CCR7
and CXCR4 ligands. Desensitization of chemotaxis experiments were
performed as described (reference 22). In brief, mouse LN or spleen cells
were pretreated with five times the optimal chemotactic dose of the indi-
cated chemokine (or control medium), and washed through a serum layer
to remove residual chemokine. The desensitized cells were then allowed
to migrate towards the same or another chemokine (at the optimal
chemotactic dose) through 5-mm pores for 15 min. Migrated cells were
counted as described (references 8, 22). Percent migration of B cells was
calculated based on FACS® analysis of migrated compared with input
cells; B cells were defined as CD32/CD191. Data shown are the mean 6
SD of three experiments, each with two replicate wells per condition.
Mean maximum migration of mock-treated control B cells to SDF-1a
was 10%, to MIP-3b 15%, and to SLC 13%. Figure 4. Interactions of T and B cells with PP-HEVs of DDD/1 ver-
sus normal mice. (A) The rolling flux of injected T cells (black bars) in
PP-HEVs is increased in SLC-deficient DDD/1 mice compared with
age-matched normal BALB/c, while B cell (hatched bars) rolling flux is
comparable. (B) T cell accumulation is severely curtailed in PP-HEVs of
DDD/1 mice; B cell accumulation is similar to control BALB/c mice.
Enriched T and B cell (107 cells each) populations were differentially la-
beled and coinjected for observation in PP-HEVs. Venular trees draining
single follicles were selected for analysis. Rolling flux is the total number
of rolling B or T cells observed over time and averaged for the number of
venules that supported rolling in the tree. Accumulation is the average
number of stuck cells of each subset in the whole tree at 8 min after injec-
tion. Data are mean results of three experimental animals of each type (6
SD). Rolling velocities of T cells in DDD/1 mice were similar to those in
wild-type BALB/c mice (range 43–191 mm/s, mean 99 6 44 SD).82 Chemokines Distinguish B vs. T Cell Interactions with HEVs
older mice. Anti-SLC reactivity appeared stronger in PPs
of young mice, and rarely, a small section of a precapillary
arteriole would display some anti-SLC reactivity (our un-
published observations). Despite high levels of injected la-
beled mAb, we were unable to detect any SLC on PP-HEVs
of DDD/1 mice (Fig. 5).
We reasoned that if T cells relied on SLC triggering of
CCR7, and there was substantial variability in PP-HEV pre-
sentation of CCR7 ligand SLC, T cell accumulation should
colocalize with SLC expression. We observed the behaviors
of T cells interacting with PP-HEVs, and then stained these
same HEVs in situ for expression of SLC. We found that T
cells rolled equally, if not more efficiently, within SLC2 HEV
segments, but almost exclusively accumulated on endothe-
lium presenting SLC (Fig. 6 and Fig. 7). Most importantly, T
cells rarely accumulated in vessels lacking detectable SLC. In
contrast, B cells accumulated without any obvious relation-
ship to SLC expression, occurring in SLC-negative as well
as -positive segments (data not shown, but see Fig. 7). These
findings not only support the differential requirement for
SLC and CCR7 in the triggering of T but not B cell arrest,
but suggest that T and B cell arresting factors can be differen-
tially displayed on distinct vascular segments.
Since B cells are recruited into follicles after entry into
PPs, we asked whether HEV segments preferentially sup-
porting B cell arrest might be adjacent to or associated with
the follicular microenvironments. We coinjected differen-
tially labeled B and T cells and evaluated their accumula-
tion in HEV segments in relation to structural features of
the PP. Follicles were identified by the autofluorescence of
abundant macrophages within germinal centers, and HEVs
could be readily identified at the end of the experiment by
injection of labeled mAb to MAdCAM-1 (e.g., see Fig. 5).
Although B and T cells could roll in virtually all HEVs, we
found a striking segregation of sticking cells: B cells prefer-
entially adhered within segments proximal to or within the
periphery of follicles, whereas T cells bound primarily to
HEVs within the interfollicular zone (Fig. 8, and see Fig. 7).
B cell arrest and accumulation in DDD/1 mice also occur
preferentially in follicle-associated HEV segments (data not
shown). Our data suggest that lymphoid microenvironmental
conditions may regulate HEV display of specialized adhe-
sion-triggering signals that, in turn, may contribute to the
selective recruitment of lymphocyte subsets into appropri-
ate follicular versus interfollicular domains.
Discussion
Tissue-selective lymphocyte homing from the blood is
controlled by a multistep process involving PTX-sensitive
heterotrimeric G protein–linked receptors. These Gai-medi-
ated signals trigger integrin-dependent sticking of rolling
lymphocytes, and likely participate in their diapedesis and
localization within tissue microenvironments. Recently,
chemokines have been highlighted as prime candidates that
provide PTX-sensitive signals mediating lymphocyte–endo-
thelial recognition and directed migration. Here, we have
investigated the role of known rapid adhesion-triggering
Figure 5. SLC is expressed on the lu-
men of PP-HEVs in normal, but not
DDD/1 mice. Confocal micrographs of
whole PPs from normal (left and right pan-
els) or DDD/1 (middle panel) mice depict-
ing localization of green anti-SLC (left and
middle panels), and lack of green staining
with a negative control hamster antibody
(right panel); and MAdCAM-11 HEVs as
red fluorescence (all three panels). mAbs to
SLC (anti–TCA-4, 4B1E7C10 [reference
17]) and MAdCAM-1 (MECA 89), or
control antibodies to DNP (UC8-19B) and
human CD44 (Hermes-1) (not shown)
were conjugated to Alexa™ 488 or Al-
exa™ 546, respectively. 50–75 mg of anti-
SLC or anti-DNP, and/or 10–20 mg anti–
MAdCAM-1 or anti-huCD44 was injected
via carotid artery cannulation in a single
bolus. Staining was evident for both SLC and MAdCAM-1 by 1 min, maximal for MAdCAM-1 by 10 min and for SLC by 15 min. Animals were
killed, and whole PPs were immediately removed for examination by confocal microscopy. Representative images (103 objective).
Figure 6. T cells preferentially accumulate in SLC1 HEVs. T cells
were observed in HEVs of normal animals as in the legend to Fig. 2. After
observations of T cell behaviors in multiple fields, SLC1 HEVs were
identified by subsequent, sequential injection of labeled anti-SLC and
anti–MAdCAM-1. MAdCAM-11 HEVs that exhibited successive seg-
ments differing only by expression of SLC were analyzed. Data are mean
results of three experiments (6 SD).83 Warnock et al.
chemokines in the recognition of PP-HEVs by circulating
B and T lymphocytes. Our data suggest that naive T cells
rely upon recognition of luminally presented SLC and use
signals mediated by CCR7 to arrest firmly in PP-HEVs. In
contrast, B cells, though capable of responding to SLC, use
distinct (or additional) mechanisms to arrest in PP-HEVs.
Furthermore, we present evidence that differential display
of SLC and B cell adhesion-triggering factors by interfollic-
ular versus follicle-associated high endothelium allows mi-
croenvironmental control of T versus B cell recruitment
from the blood.
With the results presented here, the evidence for CCR7
and SLC involvement in T cell recognition of HEVs seems
compelling. Previous studies have shown that HEVs ex-
press message for SLC (10), that SLC can trigger rapid inte-
grin-dependent arrest of naive B and T lymphocytes under
physiologic shear in vitro (8, 22), and that a selective defect
in T cell homing to LNs in DDD/1 mice is associated with
deficient SLC and MIP-3b expression (24). Here we show
that HEVs in fact display SLC protein, that desensitization
of CCR7-mediated signaling with SLC (or MIP-3b) in-
hibits T cell arrest, and that T cell accumulation correlates
with sites of SLC expression. Moreover, we show that the
T cell homing deficiency in DDD/1 mice involves a lack of
T cell adhesion-triggering responses on HEVs, a phenotype
indistinguishable from that of SLC- or MIP-3b–desensi-
tized T cells in wild-type hosts. We conclude that SLC and
its receptor CCR7 can mediate T cell recognition of HEVs
in lymphoid organs.
These studies provide the first direct evidence of chemo-
kine involvement in adhesion triggering during physiologic
lymphocyte–endothelial interactions, thus confirming the
hypothesized role of chemokines in lymphocyte–endothe-
lial cell recognition (25). Chemokine-triggered adhesion may
be part of a general paradigm in which functionally distinct
subsets of circulating lymphocytes use specialized chemo-
kine receptors, in place of or in addition to CCR7, for
homing from the blood, especially in settings of inflamma-
tion. A significant subset of circulating human memory T
cells expresses CCR7 (26; and Campbell, J.J., and L. Wu,
unpublished observation), both human and mouse memory
T cells respond to SLC and MIP-3b (11, 13, 18, 22, 27, 28),
and recent evidence indicates increased expression of CCR7
and concomitant greater response to SLC after activation
(13, 14). Thus, memory cells may also use CCR7, like na-
ive T cells, during recirculation through organized lym-
phoid tissues. Display of other chemokine receptors, such
as CXCR3, G protein–coupled receptor GPR-9-6 (CCR9),
CCR4, CCR5, and CCR6, also subdivides circulating mem-
ory cells, and may help confer unique vascular recognition
and tissue- or inflammation-selective homing properties. For
example, recent studies suggest a physiological role for CCR4
on systemic memory T cells, and its ligand thymus and acti-
vation-regulated chemokine (TARC) displayed by inflamed
venules, in the adhesion-triggering step of memory lympho-
cyte homing to cutaneous sites of inflammation (29), and po-
tentially for CCR9 and its ligand thymus-expressed chemo-
kine (TECK) in intestinal lymphocyte homing (30).
Although our studies implicate SLC receptor(s) in T cell–
HEV interactions, and demonstrate SLC presentation by HEV
Figure 7. Localization of lymphocytes
in PP-HEVs. Micrographs of accumu-
lated lymphocyte subpopulations in PPs.
(Left panel) T cells accumulated in SLC1
interfollicular segments of HEVs. (Middle
panel) B cells in SLClow HEV segments as-
sociated with primary follicles. (Right
panel) Segregation of sites of preferential
T and B cell accumulation in relation to
follicles. TRITC-labeled T (left) or B
(middle and right panels) cells and CM-
FDA-labeled T cells (right panel) were
observed in HEVs of normal animals as in
the legend to Fig. 4. In the left and middle
panels, after lymphocyte accumulation for
z10 min (see Materials and Methods), 60
mg Alexa™ 488–conjugated anti-SLC
mAb was injected intravenously to illuminate SLC-expressing HEV segments. Animals were killed, and whole PPs were removed for examination
by confocal microscopy. The location of follicles is indicated (F) (203 objective).
Figure 8. Sticking B and T cells are segregated in PP-HEVs. Accumu-
lated B and T cells in PP-HEVs of normal mice were analyzed for prefer-
ential localization after injection of equal numbers of each subset. Follicles
were identified by characteristic autofluorescence of resident dendritic
cells and macrophages. HEV segments were defined as follicular if lying
within or upon a follicle, cortical if wholly within the cortex, and crossing
when transitional from follicle to cortex. Red (T) and green (B) accumu-
lated cells were enumerated 8 min after injection in each class of vessels.
Data are presented as percentage of B or T cells observed among cells in
each vessel type; mean results of three experiments (6 SD).84 Chemokines Distinguish B vs. T Cell Interactions with HEVs
segments mediating T cell accumulation, they do not ex-
clude involvement of MIP-3b (or other unidentified CCR7
ligands) in T cell arrest. Like SLC, MIP-3b has potent
chemotactic activity for naive T and B cells, and for subsets
of memory CD4 and CD8 cells, but not for granulocytes
and monocytes (11, 22, 27, 28). Importantly, MIP-3b acts
through the same receptor as SLC, CCR7, can cross-desen-
sitize CCR7 to further signals from either MIP-3b or SLC
(22, 31), and, as we have shown here, desensitization with
MIP-3b selectively prevents accumulation of T but not B
cells in PP-HEVs. MIP-3b is expressed in lymphoid tis-
sues, notably in parafollicular and inner cortical regions of
LNs, and by LN stromal elements including dendritic cells
derived from T cell zones (11, 32). Although in situ hy-
bridization studies suggest that MIP-3b is not produced by
endothelium of HEVs, it is possible that luminal presentation
may occur by transcytosis from surrounding tissue. Indeed,
findings in other systems demonstrate that chemokines can
gain access to the venular lumen even when expressed or
introduced in a perivascular location (33). HEV presenta-
tion of MIP-3b by this mechanism may account for our in-
ability to block T cell arrest in PP-HEVs with bolus injec-
tions of anti-SLC mAbs: intravenous injection of up to 1
mg per mouse yielded only variable and incomplete inhibi-
tion of T cell accumulation, never exceeding 50% of control
(our unpublished results). However, this may also reflect in-
complete blockade of SLC in vivo, as anti-SLC mAbs accu-
mulate only slowly on HEVs (over minutes) compared with
anti–MAdCAM-1 mAbs or other anti-endothelial cell anti-
bodies we have used for in situ endothelial visualization.
Resolution of the role of MIP-3b or other CCR7 ligands in
addition to SLC will require generation of additional, high-
affinity anti-SLC and MIP-3b mAbs, and/or evaluation of
single and dual gene-targeted mice in future studies.
L-selectin, which is rapidly shed upon cross-linking, has
also been shown to transmit signals that can affect integrin af-
finity (34). Naive B and T lymphocytes interacting with PP-
HEVs rely on L-selectin for adequate attachment, and to
some degree, for rolling (2, 35). Although chemokine desen-
sitization of T lymphocytes with SLC did not affect attach-
ment and rolling, sticking was abrogated, suggesting that
L-selectin signals, if operating in this context, are insufficient
to mediate arrest. While we cannot rule out a contribution
by L-selectin signaling, particularly for B cells, it is unlikely
to be sufficient for physiological adhesion-triggering, given
that lymphocyte arrest is PTX sensitive, whereas L-selectin
signaling is not (36).
Although we have not here evaluated lymphocyte inter-
actions in situ with LN HEVs, in the course of our studies
we noted that some PLN HEVs display SLC, and that de-
sensitization with SLC or MIP-3b prevents accumulation
of injected T lymphocytes in LN as well as PP-HEVs. In
conjunction with the known deficiency in T cell homing
to LNs in DDD/1 mice, these observations suggest that
CCR7 and its ligands play comparable roles in T cell adhe-
sion triggering in LNs as in PPs. This postulate has been
confirmed in parallel studies from Stein and coworkers
(36a).
One of the most interesting discoveries here is the differ-
ential vascular interactions of B versus T cells, and their con-
trol at the level of adhesion triggering. Accumulation of T
and B cell subsets is markedly segregated in PP-HEVs, with
T cells collecting preferentially in interfollicular HEV seg-
ments, associated with high levels of local SLC expression.
Conversely, although B cells can also arrest in SLChi HEVs,
they tend to accumulate within intrafollicular HEV segments,
or segments immediately adjacent to follicles—segments
which are often SLClow/2. This microenvironmental control
of T versus B cell interactions with HEVs was surprising in
light of earlier models, which assumed that naive B and T
cells were recruited equivalently through HEVs, with segre-
gation to their appropriate compartments occurring entirely
after entry into the lymphoid tissue parenchyma (37, 38). In-
deed, earlier studies of B and T cell interactions with HEVs,
using either ex vivo Stamper-Woodruff frozen section assays
or short-term homing of adoptively transferred lymphocyte
subsets, failed to identify differential association of T versus B
cells with HEV segments (39–42; and Butcher, E.C. and I.L.
Weissman, unpublished results). This likely reflects the tech-
niques employed, which did not allow visualization of hom-
ing interactions, or, in the case of frozen section studies, may
not have adequately modeled in vivo physiology. However,
these prior studies also focused on HEV interactions in PLNs
of young mice, in which follicular domains are characteristi-
cally less prominent and less immunologically active than in
the PPs studied here. To the extent that the HEV segments
recruiting B but not T cells are induced or regulated by the
follicular microenvironment, as we propose (see below), it
seems likely that such segments would be relatively infrequent
and capable of less selective B (versus T) cell recruitment in
LNs. It is interesting to note that we have also occasionally
observed focal segregation of B and T cell accumulation in
MLNs and sheep RBC-immunized PLNs, with B greater
than T cell recruitment by subcapsular (follicle-associated)
HEVs (data not shown). (In these organs, such segregation is
less prominent than in PPs, suggesting that follicular localiza-
tion might be directed principally by chemotaxis of B cells
after extravasation.) Furthermore, consistent with our find-
ings, another study of PPs noted that B cell arrest occurs in a
wider range of vessels (by diameter) than T cells, including
smaller venules observed inside follicles (43).
In this context, it is noteworthy that early studies of T
versus B cell interaction did reveal a relative preference of
B versus T cells for PP (versus PLN) HEVs, both in ex vivo
frozen section assays and in short-term in vivo homing
studies (40, 41). This behavior may be explained in part by
the fact that naive B cells display slightly higher levels of the
intestinal PP homing receptor a4b7, and slightly lower lev-
els of PLN homing receptor L-selectin, than naive T cells
(44, 45). However, it is reasonable to propose that a higher
level of B cell adhesion-triggering factors in PP-HEVs (rel-
ative to PLN HEVs) could also contribute to their selective
localization, as well as to the greater frequency of homed B
than T cells in PPs.
The physical structure of the vasculature in PPs may also
promote the follicular localization of B cells, as PP-HEVs85 Warnock et al.
first arise from capillary arcades predominantly in or near B
cell follicles, and then drain out through parafollicular T cell
zones (46). Therefore, the majority of PP-HEVs that cells
first encounter lie within the proximal influence of B cell mi-
croenvironments, whereas T cell zones effect control over
“downstream” HEV segments. Our results show that B cells
accumulate efficiently in the upstream, high order, follicle-
associated segments in response to an as yet unidentified
adhesion-triggering factor(s). In contrast, although T cells
efficiently tether and roll in these high order (predomi-
nantly) SLClow segments in and/or near follicles, they arrest
only infrequently. Instead, T cells continue rolling down-
stream to arrest eventually in lower order SLChi HEVs lo-
cated within the interfollicular zone. B cells that escape
early recruitment to the follicular segments can also arrest
downstream on SLChi HEVs; whether SLC itself contrib-
utes to B cell arrest on these lower order vessels remains to be
determined. Thus, the selective homing of T and B cells is
determined by their signaling receptors, and not only by
disparate levels of counterreceptors for PP-HEV adhesion
molecules. Taken together, these studies demonstrate a novel
mechanism for the selective recruitment of lymphocyte
subsets to specialized lymphoid tissue domains—the differ-
ential presentation of factors that trigger firm adhesion.
The segmental control of chemokine expression, as we
have demonstrated, is most likely in response to and within
the context of microenvironmental cues. PPs and LNs can
be extensively remodeled during instances of immune or
inflammatory stimulation, and these secondary lymphoid
tissues (or their specialized domains) must be capable of rapid
and robust architectural refinement, particularly through the
specific recruitment of specialized subsets of lymphocytes
(47). It will be important to evaluate the extent to which
developing lymphoid compartments, or those undergoing
acute inflammatory reactions, display altered patterns of che-
mokine expression on HEVs and within cortical and follic-
ular compartments. Indeed, recent studies of inflamed LNs,
PPs, and spleen have demonstrated significant changes in
chemokines and adhesion molecules in response to inflam-
matory challenge, though the relationship to recruitment of
lymphocyte subsets has not been examined (48–55; and
McEvoy, L.M., unpublished observations). Taken together
with our findings, such observations suggest that lymphocyte
subset recruitment by LN and PP-HEVs may be tightly
controlled through elements of the multistep adhesion cas-
cade, and can be dynamically regulated by altered chemo-
kine display.
In addition to its role in T cell recognition of HEVs, as
evidenced here, SLC has been hypothesized to direct mi-
gration of lymphocytes and also dendritic cells to and
within lymphoid and other tissues (10, 13, 56–58). For ex-
ample, in situ hybridization and immunohistological studies
have revealed high levels of SLC message in the endothe-
lium of lymphatic openings and luminal presentation on
lymphatic vessels within extralymphoid tissues, suggesting a
potential role of SLC and CCR7 in regulating cellular
entry into afferent lymph (10, 59). Consistent with this,
recent studies have shown that activated dendritic cells up-
regulate CCR7, and have provided evidence that SLC is
required for efficient dendritic cell recruitment to drain-
ing LNs during inflammation (24, 59, 60). It is attractive to
postulate that CCR7 and SLC may play a similar role for
memory or activated lymphocytes in extravascular recruit-
ment to draining LNs via lymphatics. Furthermore, SLC
(as well as MIP-3b) is expressed by stromal cells associ-
ated with T cell zones in spleen, thymus, and other lym-
phoid structures (11, 13, 18, 24, 61, 62). Expression of
CCR7 ligands at such sites may serve to recruit or position
relevant cells to the appropriate T cell–rich zones, and/or
to ensure a close relationship between antigen-presenting
stromal cells and naive and antigen-reactive T cells. How-
ever, if T cells recruited through SLChi HEVs are tran-
siently desensitized to SLC, as is possible, regulation of dia-
pedesis and homing into T cell zones would likely require
additional chemoattractant mechanisms. If this model is
correct, one could imagine that the widespread and high
level of expression of CCR7 ligands within T cell zones
might serve more to prevent inappropriate “wandering”
or retrograde migration of T cells back to HEVs, by es-
tablishing a uniform or desensitizing field of CCR7 ago-
nists. Thus, a clear picture of the role of SLC or additional
chemotactic factors in extravasation and directed migration
of lymphocytes awaits further study.
In conclusion, we have provided direct evidence for
chemokine regulation of lymphocyte–endothelial recogni-
tion in vivo. Our results indicate that T cell arrest on HEVs
can be mediated by SLC and requires signaling through the
SLC receptor, CCR7, and demonstrate that B and T cells use
distinct adhesion-triggering factors for HEV recognition.
Furthermore, we have shown that adhesion-triggering fac-
tors for B and T cells are differentially presented in HEV
segments, conferring focussed subset recruitment to appro-
priate, well-defined microenvironments for B and T cell
localization within PPs. Thus, our findings demonstrate a
fundamental difference in the molecular requirements for T
and B cell homing, and reveal a previously unsuspected de-
gree of vascular specialization controlling selective recruit-
ment of circulating lymphocytes, determined not only by
tissue type, but also by microdomain.
Consistent with our results, Forster and colleagues (63)
have now shown that lymphocytes from CCR7-deficient
mice display reduced localization to lymphoid organs, though
whether the defect is at the level of HEV interaction or ex-
travasation was not determined. They observed significant re-
duction of B cell homing as well, especially to LNs: in light of
our findings, this may suggest that CCR7 can play a role in B
cell diapedesis.
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Note added in proof. Vassileva et al. have now shown that there are
two SLC genes in mice, and that the DDD/1 (plt) mouse mutation
is a deletion of the gene responsible for SLC expression in lym-
phoid tissues (Vassileva, G., H. Soto, A. Zlotnik, H. Nakano, T.
Kakiuchi, J.A. Hedrick, and S.A. Lira. 1999. J. Exp. Med. 190:
1183–1188).
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